Does renin-angiotensin system antagonist use reduce all-cause mortality in patients with heart failure and severe renal insufficiency?
RAS antagonist use is associated with lower all-cause mortality in patients with heart failure and severe renal insufficiency, suggesting a potential survival benefit that requires confirmation in randomized trials.
In HF with severe renal insufficiency, the use of RAS antagonists was associated with lower all-cause mortality. Prospective randomized trials are needed before these findings can be applied to clinical practice.
Edner et al. (Thu,) studied this question.